Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 63 Publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMECwNlg4KM7:TR?= MVTTRW5ITVJ?
LC-2-ad NUL5bIRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjlPIZKSzVyPUCuNFAxOzF5IN88US=> M13yUHNCVkeHUh?=
RL95-2 MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMECwOlY5KM7:TR?= Ml\PV2FPT0WU
MZ1-PC NF\MbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37Rc2lEPTB;MD6wNFA4OjlizszN NHHze5ZUSU6JRWK=
TE-8 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjuPJNxUUN3ME2wMlAxOTF5IN88US=> M{njbHNCVkeHUh?=
SW954 NUDGdoFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrXTWM2OD1yLkCwNVE6KM7:TR?= M2DzcXNCVkeHUh?=
TE-11 NFjsbZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4qyNmlEPTB;MD6wNFEzOyEQvF2= NFnnUmVUSU6JRWK=
PSN1 NFXkNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoGwTWM2OD1yLkCwNVMh|ryP MnzUV2FPT0WU
MOLT-4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlWyTWM2OD1yLkCwNVQ6KM7:TR?= MX3TRW5ITVJ?
697 NWOxfmw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVKyfmdzUUN3ME2wMlAxOTVizszN MWTTRW5ITVJ?
ETK-1 NUfHeII3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWryXJg4UUN3ME2wMlAxOTV{IN88US=> MoHSV2FPT0WU
TE-10 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMECxOVQh|ryP M3TifnNCVkeHUh?=
HUTU-80 NG\3cHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2D4RmlEPTB;MD6wNFE3QCEQvF2= M3zBeHNCVkeHUh?=
NTERA-S-cl-D1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn0[YNKSzVyPUCuNFAzODlizszN MVXTRW5ITVJ?
MFH-ino MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rKWmlEPTB;MD6wNFI3QCEQvF2= MW\TRW5ITVJ?
IA-LM MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoSyTWM2OD1yLkCwNlgh|ryP M{XjfXNCVkeHUh?=
MC116 NYPYUJpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnGNotWUUN3ME2wMlAxOjh7IN88US=> NVPQSYlHW0GQR1XS
RKO NV;YNWhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTLTWM2OD1yLkCwNlk5KM7:TR?= MW\TRW5ITVJ?
MRK-nu-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L1TWlEPTB;MD6wNFI6QSEQvF2= MWLTRW5ITVJ?
VA-ES-BJ M33BbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHqTWM2OD1yLkCwN{DPxE1? NGLp[pFUSU6JRWK=
KALS-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMECzNFgh|ryP NGLHb41USU6JRWK=
BB30-HNC NYfKSYNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK2RmFKSzVyPUCuNFA{OTRizszN MnniV2FPT0WU
ACN M3zaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLDNWFKSzVyPUCuNFA{OTZizszN MX\TRW5ITVJ?
TE-9 MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHmZY5KSzVyPUCuNFA{OjZizszN MYLTRW5ITVJ?
SIG-M5 M2DMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLPTXp2UUN3ME2wMlAxOzJ5IN88US=> MnrEV2FPT0WU
no-10 NFHqe|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLpWWZSUUN3ME2wMlAxOzZ{IN88US=> MVLTRW5ITVJ?
EW-1 M{XrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn4SXFKSzVyPUCuNFA{PzFizszN MlLyV2FPT0WU
SK-LMS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMEC0NFEh|ryP NX7BPGQ5W0GQR1XS
GT3TKB M3HGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMEC0N|Qh|ryP MULTRW5ITVJ?
ES4 NGTqfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4WzdWlEPTB;MD6wNFQ1QSEQvF2= MUDTRW5ITVJ?
IMR-5 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\2TWM2OD1yLkCwOFUh|ryP NF7YSYhUSU6JRWK=
NCI-H1648 MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XUOmlEPTB;MD6wNFQ3QSEQvF2= Mm\BV2FPT0WU
MV-4-11 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL1TmtKSzVyPUCuNFA1PzVizszN MlT2V2FPT0WU
SK-UT-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLxe49KSzVyPUCuNFA1QCEQvF2= NVnNOnJCW0GQR1XS
NB13 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwMEC0PVEh|ryP NVv6SHhlW0GQR1XS
DJM-1 MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfjfWdkUUN3ME2wMlAxPTNizszN NXiwUGNOW0GQR1XS
ES8 NX72UXpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfpO2pvUUN3ME2wMlAxPTN6IN88US=> NFKx[5hUSU6JRWK=
TE-6 NWSzOI86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnoTWM2OD1yLkCwOVch|ryP NXX5e2o4W0GQR1XS
KS-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrnfZlKSzVyPUCuNFA2QDJizszN NYrGPXFbW0GQR1XS
TE-1 MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMEC2NFYh|ryP M3TqS3NCVkeHUh?=
ATN-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTGdZE2UUN3ME2wMlAxPjB7IN88US=> M1nx[3NCVkeHUh?=
A4-Fuk M1;VO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPZTWM2OD1yLkCwOlEyKM7:TR?= MVzTRW5ITVJ?
ALL-PO NYfJVHh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLWTWM2OD1yLkCwOlMh|ryP NIewUVFUSU6JRWK=
BE-13 MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\WVWdKSzVyPUCuNFA3OzZizszN MWXTRW5ITVJ?
KM12 NFPiPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwMEC2N|ch|ryP NVrscmZnW0GQR1XS
NOS-1 M4jBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPKTWM2OD1yLkCwOlUh|ryP M4nE[3NCVkeHUh?=
SW962 NH3KdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH2xWmFKSzVyPUCuNFA3PjJizszN M{fabXNCVkeHUh?=
OCUB-M M2rISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMEC2OlIh|ryP MmfkV2FPT0WU
NCI-H510A MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnFb5cyUUN3ME2wMlAxPjZ3IN88US=> NXe1UWpuW0GQR1XS
EW-16 NVTnSYxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TZcGlEPTB;MD6wNFY6PCEQvF2= M4WxfHNCVkeHUh?=
KGN MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMEC3NVIh|ryP NWfJPXBvW0GQR1XS
LS-411N NVLLdplNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\uRVZtUUN3ME2wMlAxPzF5IN88US=> NEnabXVUSU6JRWK=
Becker NEewN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPRenl5UUN3ME2wMlAxPzJizszN MmHwV2FPT0WU
HC-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXsd|lyUUN3ME2wMlAxPzJzIN88US=> MkLGV2FPT0WU
CESS M2XUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTkUFlHUUN3ME2wMlAxPzN5IN88US=> M2H4eXNCVkeHUh?=
KURAMOCHI NHr4VYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrITWM2OD1yLkCwO|Q5KM7:TR?= NWXxU|M4W0GQR1XS
TGBC24TKB NFi2NoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHvfplKSzVyPUCuNFA4PTJizszN NUnCfGdSW0GQR1XS
SW982 MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XMbGlEPTB;MD6wNFc3PiEQvF2= MWjTRW5ITVJ?
HCE-4 NWm4RYpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMEC3Olch|ryP MVHTRW5ITVJ?
LOUCY MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMEC3O|Uh|ryP M4f2XXNCVkeHUh?=
8-MG-BA NYfJcYl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;MTWM2OD1yLkCwO|k3KM7:TR?= MWnTRW5ITVJ?
HT-144 NEfzSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrVXHkyUUN3ME2wMlAxQCEQvF2= M3zqenNCVkeHUh?=
LXF-289 MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMEC4NVgh|ryP NWj1TZEyW0GQR1XS
RS4-11 NFjjT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID4XGRKSzVyPUCuNFA5OzZizszN M4TjV3NCVkeHUh?=
DEL MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfVOIZsUUN3ME2wMlAxQDR3IN88US=> MXXTRW5ITVJ?
OCI-AML2 M{nDeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlmzTWM2OD1yLkCwPFUzKM7:TR?= M4TQ[3NCVkeHUh?=
CCRF-CEM M4ftNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMEC4O|Eh|ryP M3TEdnNCVkeHUh?=
A388 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwMEC4O|Qh|ryP NGi1U45USU6JRWK=
KNS-42 MonoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\JWmlEPTB;MD6wNFg6OSEQvF2= NUP3PWhjW0GQR1XS
OVCAR-4 NWjnSYdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwMEC5NFQh|ryP MX;TRW5ITVJ?
NCI-H1355 NHj4cZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\0TWM2OD1yLkCwPVE1KM7:TR?= M4\1bXNCVkeHUh?=
BL-70 MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULuWVhQUUN3ME2wMlAxQTNizszN M3zYdnNCVkeHUh?=
BL-41 NHTSSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTVO5V[UUN3ME2wMlAxQTN2IN88US=> NIjUTGpUSU6JRWK=
A101D NYjJNVFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz5fGNmUUN3ME2wMlAxQTZizszN MoHnV2FPT0WU
HL-60 M2\1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTxTWM2OD1yLkCwPVY3KM7:TR?= NWqwb4pMW0GQR1XS
COR-L279 NF\rV3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMEC5PVkh|ryP NFG4SXZUSU6JRWK=
NCI-SNU-16 NYLJS5c3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7iT4RlUUN3ME2wMlAyODB6IN88US=> MlfRV2FPT0WU
Calu-6 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[4NoJKSzVyPUCuNFExOTJizszN NH\icVdUSU6JRWK=
SR NVTxd45OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfDPWkyUUN3ME2wMlAyODJ4IN88US=> MXHTRW5ITVJ?
QIMR-WIL NEm3UWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnW4TWM2OD1yLkCxNFM{KM7:TR?= M2fIeXNCVkeHUh?=
LB647-SCLC M1jaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFG5[oFKSzVyPUCuNFExPTFizszN NID1WnZUSU6JRWK=
RPMI-8226 NU\zcWxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnwTWM2OD1yLkCxNVAzKM7:TR?= MX7TRW5ITVJ?
SK-PN-DW M33JcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVG4d|VqUUN3ME2wMlAyOTF{IN88US=> NIrVTIhUSU6JRWK=
SF268 M1XpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMEGxOVEh|ryP MoDEV2FPT0WU
HD-MY-Z NYXYN4xiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rtfWlEPTB;MD6wNVE3OyEQvF2= Mn3CV2FPT0WU
DOHH-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMEGyNFMh|ryP M2XnWHNCVkeHUh?=
SCC-3 M3X0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMEGyNFQh|ryP NX\vVJZDW0GQR1XS
ST486 M{n0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXLRm9KSzVyPUCuNFEzODRizszN M2H6c3NCVkeHUh?=
NALM-6 NF\oUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjvTWM2OD1yLkCxNlE1KM7:TR?= M2j1[XNCVkeHUh?=
NCI-H1436 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPvSHRKSzVyPUCuNFEzOzFizszN MX7TRW5ITVJ?
KE-37 M4\uTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMEGyN|Qh|ryP NEDwXYpUSU6JRWK=
RPMI-8402 NIK1XlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwMEGyOVYh|ryP NIfYbYZUSU6JRWK=
RXF393 M3vqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjzTYNKSzVyPUCuNFEzPTdizszN MkHkV2FPT0WU
KARPAS-45 NXLwVWFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonaTWM2OD1yLkCxNlch|ryP M1;rPHNCVkeHUh?=
HOP-62 NFjiU3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zWRmlEPTB;MD6wNVI4PiEQvF2= MXXTRW5ITVJ?
ES1 NGq2UYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nERWlEPTB;MD6wNVI5QCEQvF2= MoPRV2FPT0WU
L-363 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPCTWM2OD1yLkCxN|UyKM7:TR?= NYK2Zlk5W0GQR1XS
GI-1 MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwMEGzO|Mh|ryP NE\ocZZUSU6JRWK=
CTV-1 NHPUXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;lZ5k2UUN3ME2wMlAyPDd6IN88US=> MnGwV2FPT0WU
TE-5 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\XdVFNUUN3ME2wMlAyPDl4IN88US=> NUHje2FmW0GQR1XS
SNU-C2B MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT5[21KSzVyPUCuNFE1QTZizszN M3z4VnNCVkeHUh?=
K-562 MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLJTWM2OD1yLkCxOVE3KM7:TR?= MX3TRW5ITVJ?
SNB75 MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nDdGlEPTB;MD6wNVU1KM7:TR?= NHH5XHZUSU6JRWK=
MOLT-13 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PBVmlEPTB;MD6wNVY{PyEQvF2= M{S2d3NCVkeHUh?=
LS-123 NVPwW5I5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;iXm5OUUN3ME2wMlAyPjZ2IN88US=> MoPHV2FPT0WU
NCI-SNU-5 M{K1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIKwfYRKSzVyPUCuNFE4ODFizszN NVvueJhUW0GQR1XS
Daudi NGfoPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPRUlhFUUN3ME2wMlAyPzB6IN88US=> NIixNmRUSU6JRWK=
A253 NEHBWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TPSGlEPTB;MD6wNVc{QCEQvF2= Mlm5V2FPT0WU
TGBC1TKB MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13tW2lEPTB;MD6wNVc2OiEQvF2= Mlm3V2FPT0WU
SJSA-1 NGT5T|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[zSWhKSzVyPUCuNFE4PjdizszN NYXyUJBwW0GQR1XS
NCCIT M{G1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULJV3d4UUN3ME2wMlAyPzZ7IN88US=> MnHhV2FPT0WU
NCI-H69 NGThZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGT2XoZKSzVyPUCuNFE4PzhizszN MYXTRW5ITVJ?
SH-4 NFPUZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vpTmlEPTB;MD6wNVg6PSEQvF2= MlPCV2FPT0WU
HCC1187 M{PCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jRN2lEPTB;MD6wNVkzPCEQvF2= MUPTRW5ITVJ?
HCC1599 NVfWWJBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v0TGlEPTB;MD6wNlAzKM7:TR?= MlfoV2FPT0WU
ONS-76 M2\TXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3niTmlEPTB;MD6wNlA{PiEQvF2= NW\2dZo4W0GQR1XS
KU812 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFexe5NKSzVyPUCuNFIxOzlizszN MX\TRW5ITVJ?
ML-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zqTWlEPTB;MD6wNlA1PyEQvF2= M3rIeHNCVkeHUh?=
HCE-T NVn3S3JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPXUJJKSzVyPUCuNFIxQTJizszN Mk\vV2FPT0WU
NCI-H446 NG\WeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjPTWM2OD1yLkCyNVEzKM7:TR?= MoXIV2FPT0WU
RPMI-6666 NG\JZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUmxW2hyUUN3ME2wMlAzOTR7IN88US=> M1:3PXNCVkeHUh?=
MOLT-16 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfxO|ZnUUN3ME2wMlAzOTV|IN88US=> NWmxU|JoW0GQR1XS
JiyoyeP-2003 MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofYTWM2OD1yLkCyNVc3KM7:TR?= M{fNS3NCVkeHUh?=
MHH-PREB-1 M1;FUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjlV5ZRUUN3ME2wMlAzOTlzIN88US=> MYjTRW5ITVJ?
MC-CAR NEXGN3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LhTGlEPTB;MD6wNlMzPiEQvF2= MmPsV2FPT0WU
BC-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfLTWM2OD1yLkCyN|Q1KM7:TR?= MnzuV2FPT0WU
KINGS-1 MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXR[5hKSzVyPUCuNFI{PTVizszN Mn;jV2FPT0WU
PF-382 NI[xXXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml73TWM2OD1yLkCyN|c5KM7:TR?= MYLTRW5ITVJ?
J-RT3-T3-5 NIfTSWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2i4d2lEPTB;MD6wNlM5OyEQvF2= MVTTRW5ITVJ?
SF539 NWHJbmtoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPDTm1mUUN3ME2wMlAzPDBzIN88US=> MlvLV2FPT0WU
LB831-BLC NGXTWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDmWJc{UUN3ME2wMlAzPDh3IN88US=> NVPOWVJwW0GQR1XS
DMS-114 MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLQeWNRUUN3ME2wMlAzPTB{IN88US=> M4nUeHNCVkeHUh?=
LB1047-RCC NX;xfY55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHmZ5NKSzVyPUCuNFI2OSEQvF2= NF7sNFRUSU6JRWK=
LB771-HNC MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnQToRKSzVyPUCuNFI2OzRizszN NX[0WHA2W0GQR1XS
BB65-RCC NULsTlV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;i[GlEPTB;MD6wNlU{PCEQvF2= NY\DW2M1W0GQR1XS
BV-173 MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DJNGlEPTB;MD6wNlU2PCEQvF2= M1XGbXNCVkeHUh?=
ARH-77 M1H3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPqXpVOUUN3ME2wMlAzPjBzIN88US=> NEDzbVlUSU6JRWK=
IST-MEL1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwMEK2NlMh|ryP M{TaU3NCVkeHUh?=
NB1 MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfXNnhlUUN3ME2wMlAzPjh5IN88US=> MUDTRW5ITVJ?
EoL-1-cell NFHxcZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O0TGlEPTB;MD6wNlY5QCEQvF2= MXHTRW5ITVJ?
KY821 M{fCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HFSGlEPTB;MD6wNlY6PyEQvF2= MmXyV2FPT0WU
CMK MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHyweFZKSzVyPUCuNFI4OzRizszN MVTTRW5ITVJ?
NCI-H2126 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zEd2lEPTB;MD6wNlc3QCEQvF2= M3TOfnNCVkeHUh?=
NCI-H526 M1LQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfmTWM2OD1yLkCyPFkyKM7:TR?= MXXTRW5ITVJ?
COLO-684 MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMEK5NFgh|ryP MVXTRW5ITVJ?
NCI-H747 NWjHcHFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXETWM2OD1yLkCyPVM{KM7:TR?= M1W5bnNCVkeHUh?=
JAR MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMEK5OFYh|ryP M1nRR3NCVkeHUh?=
MEG-01 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITIbpBKSzVyPUCuNFI6PzhizszN MYHTRW5ITVJ?
MONO-MAC-6 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rqXmlEPTB;MD6wN|AzOyEQvF2= MkC2V2FPT0WU
IST-SL1 NFnnWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2WzbGlEPTB;MD6wN|A1OiEQvF2= NXnuV4RmW0GQR1XS
CPC-N M4HZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEThOmhKSzVyPUCuNFMxPzlizszN NFvYVGdUSU6JRWK=
NCI-H1963 M4POW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fqXmlEPTB;MD6wN|E{OSEQvF2= M1rTfnNCVkeHUh?=
K052 NUna[oxwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPzWY06UUN3ME2wMlA{OjR5IN88US=> MlP6V2FPT0WU
KM-H2 NXqwfW9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnL4TWM2OD1yLkCzN|A4KM7:TR?= M3LLWnNCVkeHUh?=
TE-12 NXjLVYN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLsTWM2OD1yLkCzN|A6KM7:TR?= M1LoXXNCVkeHUh?=
TK10 NWrzdXJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f0cWlEPTB;MD6wN|M2PiEQvF2= NFy5PXhUSU6JRWK=
NMC-G1 NEPTV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LHOWlEPTB;MD6wN|Q2OiEQvF2= NVT4SlR{W0GQR1XS
no-11 NGLNc2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;5e|ROUUN3ME2wMlA{PDd6IN88US=> M{C5OnNCVkeHUh?=
NCI-H524 NWrSOWdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrD[ZRKSzVyPUCuNFM2OjlizszN MWjTRW5ITVJ?
MHH-CALL-2 MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzreVhKSzVyPUCuNFM2PjJizszN NYXqSXBbW0GQR1XS
GB-1 M174cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\MTWM2OD1yLkCzOkDPxE1? MlPWV2FPT0WU
OPM-2 NFL1cpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13Vb2lEPTB;MD6wN|Y4OyEQvF2= MlvZV2FPT0WU
RH-1 M4K2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PFcWlEPTB;MD6wN|gyQSEQvF2= NEfkWGhUSU6JRWK=
NCI-H64 M2\SU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\zOWlEPTB;MD6wN|g2PyEQvF2= NHizVlVUSU6JRWK=
EVSA-T NXPjcllET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMEO5NlMh|ryP MYDTRW5ITVJ?
KARPAS-299 NF\wfHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmKxTWM2OD1yLkCzPVgh|ryP MmjPV2FPT0WU
MZ7-mel MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzqXmV6UUN3ME2wMlA1ODRizszN NVTFcINHW0GQR1XS
LB373-MEL-D NETuWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTOTWM2OD1yLkC0NVA2KM7:TR?= M3;YZnNCVkeHUh?=
HEL M{G5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[5fmdKSzVyPUCuNFQyPCEQvF2= NFjpZodUSU6JRWK=
SW872 MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L0b2lEPTB;MD6wOFIyKM7:TR?= M3PYe3NCVkeHUh?=
DU-4475 NFPKbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPZc4VKSzVyPUCuNFQzPDRizszN NXvzWFVwW0GQR1XS
IST-SL2 MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGO2NZBKSzVyPUCuNFQzPzVizszN NI\0OYRUSU6JRWK=
NCI-H82 NIfKRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT0TWM2OD1yLkC0N|A4KM7:TR?= NVnKc4p3W0GQR1XS
LC4-1 M3zBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHmTWM2OD1yLkC0N|UyKM7:TR?= M2rtW3NCVkeHUh?=
HDLM-2 MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W5OWlEPTB;MD6wOFM6OiEQvF2= NV3ETY9SW0GQR1XS
MMAC-SF M{nWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPQTos2UUN3ME2wMlA1PTN2IN88US=> M2DFXXNCVkeHUh?=
L-540 NITxToFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\CcFA5UUN3ME2wMlA1PjN7IN88US=> M4nXcnNCVkeHUh?=
MZ2-MEL MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT5fZJKSzVyPUCuNFQ4PDJizszN NGnoWWtUSU6JRWK=
LU-134-A MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFW0Z41KSzVyPUCuNFQ4PzNizszN NWrvSoJFW0GQR1XS
UACC-257 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K3VGlEPTB;MD6wOFg1QSEQvF2= MoDuV2FPT0WU
NCI-H1581 MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PvSmlEPTB;MD6wOFk2OyEQvF2= NHnuXJpUSU6JRWK=
NB17 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUW1cGN1UUN3ME2wMlA1QTd7IN88US=> MUXTRW5ITVJ?
SBC-1 NWLSdnZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLT[XFKSzVyPUCuNFUxPDJizszN MVzTRW5ITVJ?
TALL-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH2TWM2OD1yLkC1NFQ2KM7:TR?= MnXuV2FPT0WU
NCI-H1304 NH\hXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\QTWM2OD1yLkC1NlA5KM7:TR?= NYHB[mlSW0GQR1XS
NEC8 M33vXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDSSpNKSzVyPUCuNFUzQDZizszN M1ewdXNCVkeHUh?=
CAL-148 NYDw[VlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rsWWlEPTB;MD6wOVQ{QSEQvF2= MUnTRW5ITVJ?
CGTH-W-1 NVfNclhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMEW0OFkh|ryP NWCyVodLW0GQR1XS
NCI-H889 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\iTWM2OD1yLkC1OVkzKM7:TR?= NFr6Z2xUSU6JRWK=
GR-ST NHLpfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r2NGlEPTB;MD6wOVYzOSEQvF2= M4O4OXNCVkeHUh?=
KARPAS-422 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorPTWM2OD1yLkC1OlUh|ryP M1;KRXNCVkeHUh?=
RPMI-8866 NYjybFVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMEW3NVIh|ryP M4rPUHNCVkeHUh?=
SCLC-21H MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfCcm1nUUN3ME2wMlA2QDh2IN88US=> M2rDUHNCVkeHUh?=
COR-L88 NHrMb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDsdoNnUUN3ME2wMlA2QTJ5IN88US=> NWTXco93W0GQR1XS
LU-139 M3;pZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\TVmlEPTB;MD6wOVk5PiEQvF2= MYHTRW5ITVJ?
SF126 NWXoeldzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rmd2lEPTB;MD6wOlE{OyEQvF2= MnWxV2FPT0WU
NCI-H1882 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fkNGlEPTB;MD6wOlQzPCEQvF2= MlyxV2FPT0WU
EW-24 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7nTWM2OD1yLkC2OFg{KM7:TR?= Mk[0V2FPT0WU
CP67-MEL MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUeyd2ZXUUN3ME2wMlA3QDFizszN M4qyfnNCVkeHUh?=
DG-75 Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLFTWM2OD1yLkC2PFk6KM7:TR?= Ml[zV2FPT0WU
LOXIMVI NGTUS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYq2bmVwUUN3ME2wMlA4ODJ6IN88US=> MmSxV2FPT0WU
HH NXXNZ2J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXjTWM2OD1yLkC3NVU4KM7:TR?= MlHzV2FPT0WU
K5 M17CXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HZTWlEPTB;MD6wO|IzPiEQvF2= NETn[GtUSU6JRWK=
EC-GI-10 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnvfVlKSzVyPUCuNFczPTdizszN NVHKXmp4W0GQR1XS
SK-N-DZ M3:2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMEezNFch|ryP NYrSZZNWW0GQR1XS
A3-KAW NYXHWVJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK1VYlHUUN3ME2wMlA4OzVzIN88US=> NEj0UnpUSU6JRWK=
MLMA M2fTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXl[mpKSzVyPUCuNFc1PjVizszN NVz2UWtQW0GQR1XS
LB996-RCC Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\wc3NKSzVyPUCuNFc4ODdizszN NFPGVGRUSU6JRWK=
OS-RC-2 NFzi[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETuN3hKSzVyPUCuNFc4PDhizszN M3PuNHNCVkeHUh?=
CTB-1 MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMEe4NUDPxE1? Mkn6V2FPT0WU
IST-MES1 NXTHUJlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL6fXZKSzVyPUCuNFc6OTJizszN MYrTRW5ITVJ?
LS-1034 NXfEOIFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjsS3ZKSzVyPUCuNFgxOzVizszN MWXTRW5ITVJ?
HT MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMEiwPFYh|ryP NV3zdJY3W0GQR1XS
NCI-H2141 NEPaUZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfv[m9KSzVyPUCuNFgyKM7:TR?= MnryV2FPT0WU
LB2518-MEL NWL0[G1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;5Vow4UUN3ME2wMlA5OTRzIN88US=> NWPUOJNTW0GQR1XS
GI-ME-N NE\hUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzQOIZKSzVyPUCuNFg1PTJizszN MV7TRW5ITVJ?
TGW MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\0TWM2OD1yLkC4OlA4KM7:TR?= NIHqdIVUSU6JRWK=
SK-NEP-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu2TWM2OD1yLkC4OlQyKM7:TR?= M{Wyd3NCVkeHUh?=
NOMO-1 Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXMNpFKSzVyPUCuNFkzPzVizszN M{fpb3NCVkeHUh?=
ES6 M4nkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjYdZR1UUN3ME2wMlA6PTh7IN88US=> MnW4V2FPT0WU
NCI-H209 MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXmdHFKSzVyPUCuNFk4QDZizszN MV\TRW5ITVJ?
GAK MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrSTWM2OD1yLkGwNVYh|ryP MVvTRW5ITVJ?
BC-1 MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{C5fmlEPTB;MD6xNFM3OSEQvF2= MYLTRW5ITVJ?
KLE MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvCTWM2OD1yLkGwOFQ{KM7:TR?= NVX0cJR{W0GQR1XS
EW-3 M2jGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;Gc5pKSzVyPUCuNVA6QCEQvF2= M{O3O3NCVkeHUh?=
NKM-1 MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGP5WHVKSzVyPUCuNVEyKM7:TR?= MnvRV2FPT0WU
D-336MG M1;WVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T1OWlEPTB;MD6xNVI1PCEQvF2= MmC3V2FPT0WU
NB69 Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\SN5hKSzVyPUCuNVE{ODFizszN MkO3V2FPT0WU
D-263MG M3\nUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorsTWM2OD1yLkGxO|EzKM7:TR?= NV7yPY1YW0GQR1XS
KP-N-YS NX;uZWJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmOyTWM2OD1yLkGyNlkyKM7:TR?= NFWxUXRUSU6JRWK=
NCI-H1155 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHUTWM2OD1yLkGyOVU5KM7:TR?= NV;YbopnW0GQR1XS
BOKU MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;6TWM2OD1yLkGyOVc6KM7:TR?= NEj3cpBUSU6JRWK=
LAMA-84 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3KWZoxUUN3ME2wMlEzQTlizszN Ml\tV2FPT0WU
Raji MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTOTWM2OD1yLkGzNVE4KM7:TR?= M1TEOHNCVkeHUh?=
LU-65 Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMUOzNFch|ryP M33h[HNCVkeHUh?=
NCI-H187 NILTZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[yTmJKSzVyPUCuNVM6OjRizszN M2[0PXNCVkeHUh?=
GCIY M{iyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH1TWM2OD1yLkG0PVAyKM7:TR?= MYTTRW5ITVJ?
NCI-H2107 NE\pdmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTOWo1EUUN3ME2wMlE2ODhizszN NEPXUGxUSU6JRWK=
NCI-H1522 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPTTWM2OD1yLkG1NlY3KM7:TR?= NXXTboxwW0GQR1XS
NB6 NYXVd4NLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwMUW2NlMh|ryP MX3TRW5ITVJ?
EM-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnDTWM2OD1yLkG1O|A3KM7:TR?= MWXTRW5ITVJ?
HCC2218 NWDqSYtGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDiTWM2OD1yLkG1PVgh|ryP NUnZVJN[W0GQR1XS
NCI-H748 NELjRpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;LTWM2OD1yLkG2N|c3KM7:TR?= NXrIXIxtW0GQR1XS
MS-1 MojFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjGeFRKSzVyPUCuNVY2OzdizszN MnnYV2FPT0WU
NB5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzz[nlKSzVyPUCuNVY2QTdizszN NV\6RoZrW0GQR1XS
OMC-1 M322[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELoNVBKSzVyPUCuNVY3QDhizszN NVzSbYUxW0GQR1XS
NCI-H345 NYPH[ZZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\kVWlEPTB;MD6xOlkzQCEQvF2= MUjTRW5ITVJ?
L-428 Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7adpRKSzVyPUCuNVY6PDVizszN MX3TRW5ITVJ?
SCH MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMUi2PFUh|ryP NGHIdndUSU6JRWK=
NCI-H1417 NET2T|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vjNmlEPTB;MD6xPVIzPyEQvF2= M{jtN3NCVkeHUh?=
COLO-320-HSR NHOzN5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwMUm1N|Ih|ryP NFP4NohUSU6JRWK=
BT-474 NYL6OY5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMkC4PVIh|ryP NV\xcFM5W0GQR1XS
GDM-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm3TWM2OD1yLkKxPVcyKM7:TR?= MYPTRW5ITVJ?
NCI-H2196 NHvpcnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHFOI1KSzVyPUCuNlIzOzVizszN MmHWV2FPT0WU
KP-N-RT-BM-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofwTWM2OD1yLkKyN|Q6KM7:TR?= Mn;SV2FPT0WU
KNS-81-FD NGntZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTqZpdUUUN3ME2wMlIzQTV6IN88US=> NInldItUSU6JRWK=
COLO-668 NHrV[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7vfotKSzVyPUCuNlM3PzVizszN NFq2bZdUSU6JRWK=
C2BBe1 NF\wVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFO0RmdKSzVyPUCuNlY4PDdizszN M1T0XHNCVkeHUh?=
Ramos-2G6-4C10 NUHoe5dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLQboluUUN3ME2wMlI3QTV2IN88US=> MkXUV2FPT0WU
CAS-1 MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4njTGlEPTB;MD6yO|A6PiEQvF2= M3;2OnNCVkeHUh?=
GOTO NY[wW41FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moe1TWM2OD1yLkK3PFk1KM7:TR?= NHHtcJRUSU6JRWK=
LP-1 NXjEZZFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\aZ2lEPTB;MD6yPFA2PyEQvF2= MlXtV2FPT0WU
NCI-SNU-1 MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVn5R|Z2UUN3ME2wMlI6PDJ{IN88US=> M2HmdnNCVkeHUh?=
EB-3 MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PjVmlEPTB;MD6yPVk4QSEQvF2= Mmr4V2FPT0WU
MHH-NB-11 NFTNOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwM{C0NFIh|ryP MYLTRW5ITVJ?
SK-N-FI M33kR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwM{G2PVIh|ryP MoL6V2FPT0WU
HCC2157 MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2n3eWlEPTB;MD6zN|kyOyEQvF2= NXG0c2k4W0GQR1XS
SIMA MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\TRnlUUUN3ME2wMlM1PThzIN88US=> NVz6OnhSW0GQR1XS
MDA-MB-134-VI NYrDTlk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf0S3lKSzVyPUCuN|Y6OjhizszN M{jyT3NCVkeHUh?=
NCI-H1694 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLVZpRNUUN3ME2wMlM4KM7:TR?= NV2wd2h7W0GQR1XS
EHEB MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwM{mwPFUh|ryP M{nMVnNCVkeHUh?=
U-266 NIrXRmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;DTWlEPTB;MD6zPVg1PiEQvF2= MkXOV2FPT0WU
LC-1F NEO1bFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LxTWlEPTB;MD60N|c3PSEQvF2= M1PNZnNCVkeHUh?=
SHP-77 NFroUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;lTWM2OD1yLkS3PFU2KM7:TR?= NF;SPGRUSU6JRWK=
LS-513 MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHHbGFKSzVyPUCuOFk{ODdizszN M{fVPHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ERK / ERK; 

PubMed: 20068074     


Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells.

MARCKS (pSer159/163); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

Src (pTyr416); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; 

PubMed: 29849942     


OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot.

Id1; 

PubMed: 25344919     


(A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner.

MARCKS; 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

20068074 26015406 29849942 25344919
Growth inhibition assay
Cell viability; 

PubMed: 28823711     


Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.

28823711
Immunofluorescence
α-tubulin; 

PubMed: 22904633     


Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel.

Rab11a/BV9; 

PubMed: 29290815     


Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).

22904633 29290815
In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • Concentrations: 0.1-100 pM
  • Incubation Time: 72 hours
  • Method:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (Only for Reference)
Animal Research:

[4]

+ Expand
  • Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • Dosages: 20 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 853.91
Formula

C47H51NO14

CAS No. 33069-62-4
Storage powder
in solvent
Synonyms NSC 125973

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04000906 Not yet recruiting Drug: NAB paclitaxel|Drug: Cisplatin Peritoneal Carcinomatosis University Hospital Geneva September 2019 Phase 1
NCT04046887 Not yet recruiting Drug: Lonsurf|Drug: Gemcitabine|Drug: Nab-Paclitaxel Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma Patrick Joseph Loehrer Sr.|Indiana University|Taiho Oncology Inc. August 2019 Phase 1
NCT03779464 Recruiting Drug: S1 or Gemcitabine Pancreatic Cancer|Nab-paclitaxel|Gemcitabine|S1 Wuhan Union Hospital China August 1 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • Answer:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • Answer:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Paclitaxel | Paclitaxel supplier | purchase Paclitaxel | Paclitaxel cost | Paclitaxel manufacturer | order Paclitaxel | Paclitaxel distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID